{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T13:50:05Z","timestamp":1792245005942,"version":"4.4.0"},"reference-count":61,"publisher":"The Endocrine Society","issue":"Supplement_1","license":[{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Acromegaly is a chronic multisystem disorder in which biochemical control remains suboptimal for many patients. Even when control is achieved, treatment burden is often high despite surgery and a spectrum of established safe and effective therapies. In this narrative review of multinational late-stage clinical trials through October 2025, we summarize drug developments that may broaden individualized medical strategies. Oral somatostatin receptor ligands are now available in the United States, underscoring a shift toward more convenient long-term management. In parallel, non-oral innovations continue to advance. Octreotide subcutaneous depot (CAM2029) maintains biochemical control with acceptable safety and may reduce treatment burden. Emerging pituitary-directed therapy with longer application intervals (Debio 4126) also shows pharmacologic activity consistent with effective disease control. Growth hormone (GH) receptor\u2013directed agents (ALXN2420, MAR002) likewise demonstrate activity aligned with considerable biochemical and clinical benefit. Collectively, these agents may address unmet needs by broadening the scope of options to control production of hepatic insulin-like growth factor I (IGF-I) and to attenuate additional extrahepatic GH signaling. They may also help ease the practical burden of chronic therapy.<\/jats:p>","DOI":"10.1210\/clinem\/dgag144","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T11:42:39Z","timestamp":1775043759000},"page":"S146-S155","source":"Crossref","is-referenced-by-count":1,"title":["What is the future of acromegaly therapy?"],"prefix":"10.1210","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8667-0296","authenticated-orcid":false,"given":"Katharina","family":"Schilbach","sequence":"first","affiliation":[{"name":"Medizinische Klinik und Poliklinik IV, LMU Klinikum , Munich 80336 ,","place":["Germany"]},{"name":"Deggendorf Institute of Technology , Faculty of Applied Healthcare Sciences, Deggendorf 94469 ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7905-7357","authenticated-orcid":false,"given":"Christian J","family":"Strasburger","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin, Berlin Institute of Health , Berlin 10117 ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2026,4,8]]},"reference":[{"issue":"11","key":"2026060416144669200_dgag144-B1","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/s41574-025-01148-2","article-title":"Consensus on acromegaly therapeutic outcomes: an update","volume":"21","author":"Melmed","year":"2025","journal-title":"Nat Rev Endocrinol"},{"issue":"6","key":"2026060416144669200_dgag144-B2","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1210\/endrev\/bnaf020","article-title":"Medical treatment of acromegaly: navigating the present, shaping the future","volume":"46","author":"Gadelha","year":"2025","journal-title":"Endocr Rev"},{"issue":"1","key":"2026060416144669200_dgag144-B3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11102-020-01091-7","article-title":"A pituitary society update to acromegaly management guidelines","volume":"24","author":"Fleseriu","year":"2021","journal-title":"Pituitary"},{"issue":"4","key":"2026060416144669200_dgag144-B4","doi-asserted-by":"crossref","first-page":"e1323","DOI":"10.1210\/clinem\/dgad568","article-title":"New treatments for acromegaly in development","volume":"109","author":"Gadelha","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2026060416144669200_dgag144-B5","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1210\/clinem\/dgab874","article-title":"State of the art of patient-reported outcomes in acromegaly or GH deficiency: a systematic review and meta-analysis","volume":"107","author":"van der Meulen","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2026060416144669200_dgag144-B6","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1530\/EJE-20-0019","article-title":"Prolonged diagnostic delay in acromegaly is associated with increased morbidity and mortality","volume":"182","author":"Esposito","year":"2020","journal-title":"Eur J Endocrinol"},{"key":"2026060416144669200_dgag144-B7","doi-asserted-by":"crossref","first-page":"7206713","DOI":"10.1155\/2022\/7206713","article-title":"Pituitary adenoma surgery survey: neurosurgical centers and pituitary adenomas","volume":"2022","author":"Netuka","year":"2022","journal-title":"Int J Endocrinol"},{"issue":"5","key":"2026060416144669200_dgag144-B8","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s11102-017-0838-2","article-title":"Criteria for the definition of pituitary tumor centers of excellence (PTCOE): a pituitary society statement","volume":"20","author":"Casanueva","year":"2017","journal-title":"Pituitary"},{"key":"2026060416144669200_dgag144-B9","doi-asserted-by":"crossref","first-page":"816426","DOI":"10.3389\/fendo.2022.816426","article-title":"Acromegaly: clinical care in central and eastern Europe, Israel, and Kazakhstan","volume":"13","author":"Bolanowski","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"2026060416144669200_dgag144-B10","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1530\/EJE-15-1042","article-title":"Patient-reported outcomes of parenteral somatostatin analogue injections in 195 patients with acromegaly","volume":"174","author":"Strasburger","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"2026060416144669200_dgag144-B11","doi-asserted-by":"crossref","first-page":"101893","DOI":"10.1016\/j.beem.2024.101893","article-title":"Predictors of biochemical response to somatostatin receptor ligands in acromegaly","volume":"38","author":"Marazuela","year":"2024","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"6","key":"2026060416144669200_dgag144-B12","doi-asserted-by":"crossref","first-page":"D17","DOI":"10.1530\/EJE-19-0998","article-title":"Pegvisomant and not somatostatin receptor ligands (SRLs) is first-line medical therapy for acromegaly","volume":"182","author":"van der Lely","year":"2020","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"2026060416144669200_dgag144-B13","doi-asserted-by":"crossref","first-page":"e3785","DOI":"10.1210\/clinem\/dgaa526","article-title":"Maintenance of acromegaly control in patients switching from injectable somatostatin receptor ligands to oral octreotide","volume":"105","author":"Samson","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2026060416144669200_dgag144-B14","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1530\/EJE-22-0220","article-title":"Durable biochemical response and safety with oral octreotide capsules in acromegaly","volume":"187","author":"Samson","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"2026060416144669200_dgag144-B15"},{"key":"2026060416144669200_dgag144-B16","author":"Lee"},{"issue":"1","key":"2026060416144669200_dgag144-B17","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1210\/clinem\/dgae385","article-title":"Acromegaly disease control maintained after switching from injected somatostatin receptor ligands to oral paltusotine","volume":"110","author":"Gadelha","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"2026060416144669200_dgag144-B18","doi-asserted-by":"crossref","first-page":"e1050","DOI":"10.1210\/clinem\/dgaf579","article-title":"Rapid and sustained response of biochemically uncontrolled acromegaly to once-daily oral paltusotine treatment","volume":"111","author":"Biller","year":"2026","journal-title":"J Clin Endocrinol Metab"},{"key":"2026060416144669200_dgag144-B19","author":"Oczyesa | European Medicines Agency"},{"issue":"6","key":"2026060416144669200_dgag144-B20","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1210\/clinem\/dgae707","article-title":"Octreotide subcutaneous depot for acromegaly: a randomized, double-blind, placebo-controlled phase 3 trial, ACROINNOVA 1","volume":"110","author":"Ferone","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026060416144669200_dgag144-B21","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1477-7525-2-13","article-title":"Acromegaly quality of life questionnaire (AcroQoL)","volume":"2","author":"Badia","year":"2004","journal-title":"Health Qual Life Outcomes"},{"issue":"9","key":"2026060416144669200_dgag144-B22","doi-asserted-by":"crossref","first-page":"S202","DOI":"10.1016\/j.eprac.2025.05.580","article-title":"CAM2029, an octreotide subcutaneous FluidCrystal\u00ae depot, provides biochemical control of acromegaly and improves patient-reported outcomes: interim results from the phase 3 ACROINNOVA 2 trial","volume":"31","author":"Silverstein","year":"2025","journal-title":"Endocr Pract"},{"issue":"6","key":"2026060416144669200_dgag144-B23","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1172\/JCI0215463","article-title":"Circulating levels of IGF-1 directly regulate bone growth and density","volume":"110","author":"Yakar","year":"2002","journal-title":"J Clin Invest"},{"issue":"2","key":"2026060416144669200_dgag144-B24","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1210\/endo.133.2.7688291","article-title":"Growth hormone (GH) stimulates insulin-like growth factor-I (IGF-I) and IGF-I-binding protein-3, but not GH receptor gene expression in livers of juvenile rats","volume":"133","author":"Domen\u00e9","year":"1993","journal-title":"Endocrinology"},{"issue":"12","key":"2026060416144669200_dgag144-B25","first-page":"4712","article-title":"Insulin regulation of human hepatic growth hormone receptors: divergent effects on biosynthesis and surface translocation","volume":"85","author":"Leung","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026060416144669200_dgag144-B26","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1530\/EJE-10-0969","article-title":"Hypothesis: extra-hepatic acromegaly: a new paradigm?","volume":"164","author":"Neggers","year":"2011","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2026060416144669200_dgag144-B27","first-page":"55","article-title":"Growth hormone and bone","volume":"19","author":"Ohlsson","year":"1998","journal-title":"Endocr Rev"},{"issue":"4","key":"2026060416144669200_dgag144-B28","first-page":"157","article-title":"Endocrine regulation of the growth plate","volume":"64","author":"Nilsson","year":"2005","journal-title":"Horm Res"},{"issue":"11","key":"2026060416144669200_dgag144-B29","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1172\/JCI42447","article-title":"Distinct growth hormone receptor signaling modes regulate skeletal muscle development and insulin sensitivity in mice","volume":"120","author":"Mavalli","year":"2010","journal-title":"J Clin Invest"},{"issue":"3","key":"2026060416144669200_dgag144-B30","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41574-019-0280-9","article-title":"The effects of growth hormone on adipose tissue: old observations, new mechanisms","volume":"16","author":"Kopchick","year":"2020","journal-title":"Nat Rev Endocrinol"},{"issue":"8","key":"2026060416144669200_dgag144-B31","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1007\/s00467-021-05097-6","article-title":"Renal effects of growth hormone in health and in kidney disease","volume":"36","author":"Haffner","year":"2021","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"2026060416144669200_dgag144-B32","first-page":"66","article-title":"Extra-hepatic acromegaly","volume":"9","author":"Franck","year":"2013","journal-title":"Eur Endocrinol"},{"issue":"3","key":"2026060416144669200_dgag144-B33","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1210\/clinem\/dgaa859","article-title":"Discordant GH and IGF-1 results in treated acromegaly: impact of GH cutoffs and mean values assessment","volume":"106","author":"Campana","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026060416144669200_dgag144-B34","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s12020-015-0810-8","article-title":"Combined treatment of somatostatin analogues with pegvisomant in acromegaly","volume":"52","author":"Franck","year":"2016","journal-title":"Endocrine"},{"issue":"3","key":"2026060416144669200_dgag144-B35","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1172\/JCI19933","article-title":"Central and peripheral actions of somatostatin on the growth hormone-IGF-I axis","volume":"114","author":"Murray","year":"2004","journal-title":"J Clin Invest"},{"issue":"1","key":"2026060416144669200_dgag144-B36","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s11102-023-01360-1","article-title":"Consensus on criteria for acromegaly diagnosis and remission","volume":"27","author":"Giustina","year":"2024","journal-title":"Pituitary"},{"issue":"16","key":"2026060416144669200_dgag144-B37","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1056\/NEJM200004203421604","article-title":"Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant","volume":"342","author":"Trainer","year":"2000","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"2026060416144669200_dgag144-B38","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1530\/eje.0.148s021","article-title":"Discovery and mechanism of action of pegvisomant","volume":"148","author":"Kopchick","year":"2003","journal-title":"Eur J Endocrinol"},{"issue":"8","key":"2026060416144669200_dgag144-B39","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1210\/endo.140.8.7047","article-title":"The human growth hormone antagonist B2036 does not interact with the prolactin receptor","volume":"140","author":"Goffin","year":"1999","journal-title":"Endocrinology"},{"issue":"6185","key":"2026060416144669200_dgag144-B40","doi-asserted-by":"crossref","first-page":"1249783","DOI":"10.1126\/science.1249783","article-title":"Mechanism of activation of protein kinase JAK2 by the growth hormone receptor","volume":"344","author":"Brooks","year":"2014","journal-title":"Science"},{"key":"2026060416144669200_dgag144-B41","doi-asserted-by":"crossref","first-page":"e38089","DOI":"10.7554\/eLife.38089","article-title":"Receptor-mediated dimerization of JAK2 FERM domains is required for JAK2 activation","volume":"7","author":"Ferrao","year":"2018","journal-title":"Elife"},{"issue":"6589","key":"2026060416144669200_dgag144-B42","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1126\/science.abn8933","article-title":"Structure of a Janus kinase cytokine receptor complex reveals the basis for dimeric activation","volume":"376","author":"Glassman","year":"2022","journal-title":"Science"},{"issue":"4","key":"2026060416144669200_dgag144-B43","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1530\/EJE-17-0996","article-title":"Increasing frequency of combination medical therapy in the treatment of acromegaly with the GH receptor antagonist pegvisomant","volume":"178","author":"Strasburger","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"2026060416144669200_dgag144-B44","author":"Debio 4126"},{"issue":"1","key":"2026060416144669200_dgag144-B45","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0950-351X(96)80362-4","article-title":"Somatostatin receptors and disease: role of receptor subtypes","volume":"10","author":"Hofland","year":"1996","journal-title":"Baillieres Clin Endocrinol Metab"},{"key":"2026060416144669200_dgag144-B46","author":"Bellon"},{"issue":"8","key":"2026060416144669200_dgag144-B47","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1517\/14740338.2015.1059817","article-title":"Adverse events associated with somatostatin analogs in acromegaly","volume":"14","author":"Grasso","year":"2015","journal-title":"Expert Opin Drug Saf"},{"key":"2026060416144669200_dgag144-B48","author":"Menetrey"},{"issue":"Suppl 1","key":"2026060416144669200_dgag144-B49","doi-asserted-by":"crossref","first-page":"A511","DOI":"10.1210\/jendso\/bvac150.1062","article-title":"ODP353 sustained suppression of IGF1 with AZP-3813, a bicyclic 16-amino acid peptide antagonist of the human growth hormone receptor and a potential new treatment for acromegaly","volume":"6","author":"Culler","year":"2022","journal-title":"J Endocr Soc"},{"issue":"3","key":"2026060416144669200_dgag144-B50","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1093\/ejendo\/lvaf043","article-title":"Additive effects of ALXN2420, a GH receptor antagonist, and octreotide on IGF1 suppression in vivo","volume":"192","author":"Ravel","year":"2025","journal-title":"Eur J Endocrinol"},{"key":"2026060416144669200_dgag144-B51","first-page":"Unit 19.13","article-title":"Overview of Biacore systems and their applications","volume":"Chapter 19","author":"Jason-Moller","year":"2006","journal-title":"Curr Protoc Protein Sci"},{"issue":"Suppl 1","key":"2026060416144669200_dgag144-B52","doi-asserted-by":"crossref","first-page":"bvae163.1100","DOI":"10.1210\/jendso\/bvae163.1100","article-title":"8406 A phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of AZP-3813, a novel small peptide growth hormone receptor antagonist, in healthy subjects","volume":"8","author":"Allas","year":"2024","journal-title":"J Endocr Soc"},{"key":"2026060416144669200_dgag144-B53","author":"Alexion Pharmaceuticals, Inc"},{"issue":"Suppl_1","key":"2026060416144669200_dgag144-B54","doi-asserted-by":"crossref","first-page":"bvaf149.1473","DOI":"10.1210\/jendso\/bvaf149.1473","article-title":"OR12-06 Development of a novel growth hormone receptor antagonist antibody for the treatment of acromegaly","volume":"9","author":"Kurylo","year":"2025","journal-title":"J Endocr Soc"},{"key":"2026060416144669200_dgag144-B55"},{"key":"2026060416144669200_dgag144-B56"},{"issue":"2","key":"2026060416144669200_dgag144-B57","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1530\/EJE-18-0138","article-title":"A randomised, open-label, parallel group phase 2 study of antisense oligonucleotide therapy in acromegaly","volume":"179","author":"Trainer","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"Suppl 1","key":"2026060416144669200_dgag144-B58","doi-asserted-by":"crossref","first-page":"A526","DOI":"10.1210\/jendso\/bvac150.1095","article-title":"OR27-4 placebo-controlled and open-label extension study of a novel hepatic-targeted antisense cimdelirsen (IONIS-GHR-LRx) under investigation in acromegaly patients","volume":"6","author":"Bhanot","year":"2022","journal-title":"J Endocr Soc"},{"issue":"2","key":"2026060416144669200_dgag144-B59","doi-asserted-by":"crossref","first-page":"101710","DOI":"10.1016\/j.ando.2025.101710","article-title":"New treatments for acromegaly: is a revolution underway?","volume":"86","author":"Cristante","year":"2025","journal-title":"Ann Endocrinol (Paris)"},{"issue":"9","key":"2026060416144669200_dgag144-B60","doi-asserted-by":"crossref","first-page":"e3644","DOI":"10.1210\/clinem\/dgac385","article-title":"IGF-I variability over repeated measures in patients with acromegaly under long-acting somatostatin receptor ligands","volume":"107","author":"Maione","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026060416144669200_dgag144-B61","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1093\/ejendo\/lvaf200","article-title":"Insulin-like growth factor-I and symptoms of acromegaly according to time since somatostatin receptor ligand injection","volume":"193","author":"Remba-Shapiro","year":"2025","journal-title":"Eur J Endocrinol"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgag144\/67989321\/dgag144.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/Supplement_1\/S146\/67989321\/dgag144.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/Supplement_1\/S146\/67989321\/dgag144.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T20:14:59Z","timestamp":1780604099000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/111\/Supplement_1\/S146\/8643936"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,8]]},"references-count":61,"journal-issue":{"issue":"Supplement_1","published-online":{"date-parts":[[2026,4,8]]},"published-print":{"date-parts":[[2026,6,4]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgag144","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,4,8]]}}}